Kane Biotech presents revyve wound care data

Executive Summary

• Kane Biotech presented novel preclinical data and clinical case study findings for its product revyve at two major North American wound care conferences: the NSWOCC 44th National Conference and the Symposium on Advanced Wound Care (SAWC) Spring Conference.
• Preclinical in vitro studies demonstrated significant inhibition of key proteases associated with non-healing chronic wounds, including an 80-82% reduction in MMP and elastase activity, and 100% reduction in collagenase and TACE enzyme activity.
• Clinical case series presented at NSWOCC showed clinically meaningful reductions in wound size, pain, and exudate, along with improved tissue regranulation in patients with complex chronic lesions over periods of 2 to 12 weeks.

Key Details

• Preclinical Data (SAWC):
  • In vitro models demonstrated an 80% reduction in Matrix Metalloproteinases (MMP) activity.
  • 82% reduction in elastase activity.
  • 100% reduction in collagenase and TNF-Alpha Converting Enzyme (TACE) activity.
  • Data supports exploration into chronic wound mechanisms, noting TNF-alpha levels in chronic wounds may exceed acute wounds by up to 100-fold.
• Clinical Case Studies (NSWOCC):
  • Kane showcased four case study posters and delivered an oral presentation titled "Changing the Paradigm of Wound Care Through the Use of Novel Modalities."
  • Case 1: Observed reduction in wound size over three weeks and reported quality of life improvement in a pressure wound case.
  • Case 2: 60% wound size reduction over two months in a venous leg ulcer.
  • Case 3: Reported pain elimination and exudate reduction in a painful pressure wound.
  • Case 4: Observed healing progression in a venous leg ulcer with associated pain improvement over six weeks.
• Product Focus:
  • Presentations featured revyve antimicrobial wound gel and the XSONX wound hygiene system.
  • Kane representatives engaged with healthcare professionals, providing educational materials and product demonstrations.
• Strategic Context:
  • Interim CEO Dr. Robert Huizinga stated these presentations are part of an expansion of the market support plan for revyve, demonstrating clinical value and commercial potential.
  • Additional data presentations are expected throughout the current and following year.

Notable Quotes

• "Since its approval by Health Canada, revyve has been evaluated in a case series with encouraging results. It was shown to convert non-healing wounds to healing wounds in real patients with complex chronic lesions," — Dr. Rohan Pointer, Medical Director, Kane Biotech.
• "At Kane, we are encouraged by the in vitro and early clinical observations shared at these conferences. These insights point to the potential role of revyve in supporting wound hygiene and care for patients with complex lesions." — Dr. Rohan Pointer, Medical Director, Kane Biotech.
• "Clinical conferences are an opportunity for Kane to reinforce our innovation in wound care... We look forward to presenting additional data throughout this year and next." — Dr. Robert Huizinga, Interim Chief Executive Officer, Kane Biotech.